Boots Centre for Innovation appoints scientific advisor, link to industry
This article was originally published in Clinica
Executive Summary
The UK's Boots Centre for Innovation has appointed James Ellis as a second, concurrent scientific advisor, in a move that is said to respond to a "huge response from innovators". His remit will be to work, alongside existing scientific advisor Ryan Bamsey, with business development managers, academics and industry to identify new product opportunities and encourage entrepreneurs to bring their pioneering ideas forward. Having worked for a number of university spin-out companies, Dr Ellis is said to have a "thorough knowledge of the difficulties entrepreneurs often face in finding a route to market". The Swansea, Wales-based Boots Centre for Innovation was set up in 2007 to identify and facilitate the development of pioneering healthcare products, and claims to have received more than 400 proposals.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.